Genetic and nucleic-acid-based interventions offer a promising alternative approach; for example, RNAi mediated inhibition of the oncogenic transporter SLC39A4 has been extensively validated in preclinical models of pancreatic, gallbladder, and nasopharyngeal carcinomas, where it suppresses tumor growth and overcomes chemoresistance (10, 232, 233). Here, SLC39A4 is linked to neoplasm.